This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NeuroSense Therapeutics Ltd. Announces Additional Positive Results from its 12-Month PARADIGM Phase 2b Study of PrimeC in ALS Patients CI
NeuroSense Therapeutics Ltd. Reports Statistically Significant Results from the 12-Month Paradigm Study Evaluating PrimeC in People Living with Amyotrophic Lateral Sclerosis CI
Global markets live: Novo Nordisk, Apple, UPS, Eli Lilly, Qualcomm... Our Logo
NeuroSense Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
NeuroSense Therapeutics Receives Delisting Notice From Nasdaq MT
NeuroSense Partners with PhaseV for ALS Treatment Trial -- Shares Up MT
NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients CI
NeuroSense Therapeutics Ltd. announced that it has received $4.47 million in funding CI
NeuroSense to Collaborate With Genetika+ on Alzheimer's Disease Drug Development; Shares Fall MT
NeuroSense Therapeutics Ltd. and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease CI
NeuroSense Therapeutics Ltd. Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting CI
NeuroSense Therapeutics Prices $4.5 Million Offering of Ordinary Shares, Warrants MT
NeuroSense Therapeutics Ltd. announced that it expects to receive $4.47 million in funding CI
NeuroSense Therapeutics Ltd. Collaborates with Lonza to Identify Exosome-Based Biomarkers, in Order to Advance Neurodegenerative Disease Treatments and Diagnostics CI
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Neurosense Therapeutics Ltd. Reports Additional Positive Results from Its ALS Phase 2B Paradigm Trial CI
NeuroSense Gets Non-Compliance Notice From Nasdaq MT
Neurosense Therapeutics Ltd. Reports Additional Positive Efficacy Data from Further Evaluation of Its Phase 2B Als Trial CI
NeuroSense Therapeutics Ltd.'s Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints CI
Top Premarket Gainers MT
NeuroSense Therapeutics Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Neurosense Receives U.S. Fda Confirmation of Cmc Strategy for Primec in Preparation for Pivotal Phase 3 in Als and Commercial Readiness CI
NeuroSense Therapeutics Ltd. Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 CI
Neurosense Therapeutics Ltd. Announces Results of Non-Sponsored in Vitro Study of PrimeC in Amyotrophic Lateral Sclerosis CI
Neurosense Therapeucs Ltd. Opens an Eu Office CI
Chart NeuroSense Therapeutics Ltd.
More charts
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7316 USD
Average target price
5.25 USD
Spread / Average Target
+617.61%
Consensus
  1. Stock Market
  2. Equities
  3. NRSN Stock
  4. News NeuroSense Therapeutics Ltd.
  5. NeuroSense Therapeutics Receives Delisting Notice From Nasdaq